Drug makers in the dark on plan for subsidies

Wylot, Robert
March 2002
Warsaw Business Journal;3/11/2002, Vol. 8 Issue 10, p1
Reports the plans of the government to reduce subsidies for drugs in Poland. Number of drugs the company will eliminate from the refund list; Effect of the government reluctance from disclosing plan details on the businesses of the drug industry; Statement regarding the refund limits by spokeswoman of the Health Ministry.


Related Articles

  • Ruling overturned: Michigan Rx plan goes into effect.  // Medical Marketing & Media;Feb2002, Vol. 37 Issue 2, p6 

    Reports on the effects of requiring additional price discounts from Michigan drug companies in the industry. Views of PhRMA organization on the implementation of the price discount policy; Refusal of Pfizer company to participate the program; Reduction of sales.

  • States tighten squeeze on Medicaid payments; generic drug firms reject price cut. Liebman, Milton // Medical Marketing & Media;Sep2002, Vol. 37 Issue 9, p18 

    Reports on the refusal of the pharmaceutical companies to give mandated rebates in Missouri. Participation in a state Medicaid program; Reduction of the provider payments; Application of lawsuits against the state.

  • STATE ACTION.  // Pharmaceutical Executive;Feb2002, Vol. 22 Issue 2, p22 

    Reports on the implication of a Florida program that would require pharmaceutical companies to offer the state rebates to be included on a list of preferred Medicaid drugs. Lawsuit filed by PhRMA to stop the initiative; Sale of GlaxoSmithKline's antimigraine drug Imitrex.

  • Senate vote continues rebates by pharmaceutical manufacturers.  // Drug Store News;10/23/95, Vol. 17 Issue 17, p21 

    Reports on the US Senate Finance Committee's vote to continue requiring pharmaceutical manufacturers to pay multi-million dollar rebates for their drugs to gain access to the Medicaid program. Possibilities of reducing pharmacy reimbursements without the rebates.

  • PHARMACEUTICAL REBATES ON THE HOT SEAT. Gebhart, Fred // Drug Topics;1/20/2003, Vol. 147 Issue 2, p40 

    Discusses issues pertaining to pharmaceutical manufacturer rebates in the U.S. Background on the case filed against the Medco Health Solutions, a pharmacy benefit manager company, for misrepresentation of cost savings; Problems related to rebate percentages.

  • How safe are the harbors?  // Drug Topics;1/20/2003, Vol. 147 Issue 2, p44 

    Discusses the development of compliance guidelines by the U.S. Department of Health and Human Services on rebate kickbacks and illegal payments for pharmaceutical manufacturers. Implications of the anti-kickback statute for the use of rebate strategies.

  • Do rebates boost prices?  // Drug Topics;1/20/2003, Vol. 147 Issue 2, p46 

    Studies results of a research study which concluded that U.S. federal laws that require drug manufacturers to match their lowest non-Medicaid prices on all sales to Medicaid and other select programs have increased drug costs in 2002. Tendency for drug manufacturers to use rebate strategies to...

  • Pharmaceuticals Industry to Appeal Florida Rebate Rule.  // Chemical Market Reporter;1/7/2002, Vol. 261 Issue 1, p18 

    Reports that the pharmaceutical industry will appeal a ruling that upheld a Florida state law which seeks rebates from drug companies in return of being included on a list of preferred Medicaid drug suppliers. Impact of the decision of a federal judge in Tallahassee on the industry; View of the...

  • One generic firm makes concession.  // Drug Topics;9/2/2002, Vol. 146 Issue 17, p5 

    Reports that the TEVA Pharmaceutical Industries Inc. has agreed to pay rebates to Missouri for taking part in its drug assistance program for senior citizens that started in July 2002.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics